Less invasive is not always better
Less invasive is not always better, Published online: 21 November 2018; doi:10.1038/s41571-018-0133-9Less invasive is not always better (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 21, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Reduced MHCII levels in relapsed AML
Reduced MHCII levels in relapsed AML, Published online: 19 November 2018; doi:10.1038/s41571-018-0132-xReduced MHCII levels in relapsed AML (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 19, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Lessons learned from a multicentre clinical trial in Africa
Lessons learned from a multicentre clinical trial in Africa, Published online: 15 November 2018; doi:10.1038/s41571-018-0121-0The International Society of Paediatric Oncology (SIOP)–Paediatric Oncology in Developing Countries (PODC) Collaborative Wilms Tumour Africa project delivered treatment in eight centres across five countries in sub-Saharan Africa. Setting up a collaboration like this is easier said than done, and herein we share the lessons we learned along the way. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 15, 2018 Category: Cancer & Oncology Authors: Trijn Israels Elizabeth M. Molyneux Source Type: research

Addendum: Low-value approvals and high prices might incentivize ineffective drug development
Addendum: Low-value approvals and high prices might incentivize ineffective drug development, Published online: 12 November 2018; doi:10.1038/s41571-018-0120-1Addendum: Low-value approvals and high prices might incentivize ineffective drug development (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 12, 2018 Category: Cancer & Oncology Authors: Vinay Prasad Christopher McCabe Sham Mailankody Source Type: research

Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned
Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned, Published online: 09 November 2018; doi:10.1038/s41571-018-0116-xBroad population screening of asymptomatic individuals for cancers of the prostate or thyroid has resulted in overdiagnosis and overtreatment. Herein, the authors describe the epidemiology, pathology, and screening guidelines for the management of patients with those cancers, and discuss existing international active surveillance protocols. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 9, 2018 Category: Cancer & Oncology Authors: Lisa M. Lowenstein Spyridon P. Basourakos Michelle D. Williams Patricia Troncoso Justin R. Gregg Timothy C. Thompson Jeri Kim Source Type: research

Olaparib maintenance moves to first line
Olaparib maintenance moves to first line, Published online: 08 November 2018; doi:10.1038/s41571-018-0126-8Olaparib maintenance moves to first line (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 8, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

New window of opportunity with ICIs in melanoma
New window of opportunity with ICIs in melanoma, Published online: 08 November 2018; doi:10.1038/s41571-018-0124-xNew window of opportunity with ICIs in melanoma (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 8, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Benefit in patients with PD-L1-positive TNBC
Benefit in patients with PD-L1-positive TNBC, Published online: 06 November 2018; doi:10.1038/s41571-018-0127-7Benefit in patients with PD-L1-positive TNBC (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Time to abandon single-site irradiation for inducing abscopal effects
Time to abandon single-site irradiation for inducing abscopal effects, Published online: 06 November 2018; doi:10.1038/s41571-018-0119-7Many clinical trials are testing the safety and/or efficacy of combining radiotherapy with immunotherapy, nearly all using a single-site irradiation (or ‘abscopal’) approach, but emerging evidence suggests that this approach likely produces suboptimal results. The authors of this Perspective provide a biological rationale supporting the abandonment of the abscopal approach, and instead advocate exploring comprehensive irradiation of multiple/all lesions. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 6, 2018 Category: Cancer & Oncology Authors: Eric D. Brooks Joe Y. Chang Source Type: research

Benefit with VR-CAP in mantle cell lymphoma
Benefit with VR-CAP in mantle cell lymphoma, Published online: 06 November 2018; doi:10.1038/s41571-018-0130-zBenefit with VR-CAP in mantle cell lymphoma (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Outcomes depend on tumour histology
Outcomes depend on tumour histology, Published online: 06 November 2018; doi:10.1038/s41571-018-0129-5Outcomes depend on tumour histology (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Interferon enhances immune-checkpoint inhibition
Interferon enhances immune-checkpoint inhibition, Published online: 06 November 2018; doi:10.1038/s41571-018-0128-6Interferon enhances immune-checkpoint inhibition (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Survival data from PALOMA-3 reported
Survival data from PALOMA-3 reported, Published online: 05 November 2018; doi:10.1038/s41571-018-0125-9Survival data from PALOMA-3 reported (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 5, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Neuroendocrine neoplasia goes molecular — time for a change
Neuroendocrine neoplasia goes molecular — time for a change, Published online: 02 November 2018; doi:10.1038/s41571-018-0118-8In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 2, 2018 Category: Cancer & Oncology Authors: Guido Rindi Bertram Wiedenmann Source Type: research

Long-term benefits in COMBI-AD
Long-term benefits in COMBI-AD, Published online: 01 November 2018; doi:10.1038/s41571-018-0122-zLong-term benefits in COMBI-AD (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 1, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research